Research programme: glucokinase stimulants - Hua Medicine/Roche

Drug Profile

Research programme: glucokinase stimulants - Hua Medicine/Roche

Alternative Names: GKA programme - Hua Medicine/Roche; Glucokinase activator programme - Hua Medicine/Roche; RO 0281675

Latest Information Update: 30 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Hua Medicine; Roche
  • Class Acrylamides; Small molecules
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 30 Oct 2013 No development reported - Preclinical for Type-2 diabetes mellitus in USA (PO)
  • 20 Dec 2011 Roche's glucokinase activator programme licensed to Hua Medicine worldwide, including the lead candidate RO 5305552
  • 01 Oct 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top